Status:
TERMINATED
68Ga-citrate PET/MR Imaging for Glioma
Lead Sponsor:
Susan Chang
Collaborating Sponsors:
American Brain Tumor Association
Conditions:
Glioma
Eligibility:
All Genders
18-85 years
Brief Summary
This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care...
Eligibility Criteria
Inclusion
- World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery
- Age \>= 18 yrs.
- Karnofsky performance status of \>= 60
- Ability to understand a written informed consent document, and the willingness to sign it.
- Cohort A:
- \- Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy
- Cohort B:
- \- Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy
Exclusion
- Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)
- Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)
Key Trial Info
Start Date :
February 26 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 24 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03335280
Start Date
February 26 2019
End Date
April 24 2020
Last Update
May 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143